Neurology Clinic, 1st General Hospital of Thessaloniki "Agios Pavlos", Thessaloniki, Greece.
Greek Association of Alzheimer's Disease and Related Disorders, Thessaloniki, Greece.
Neurodegener Dis. 2018;18(4):216-224. doi: 10.1159/000491764. Epub 2018 Sep 11.
Apolipoprotein E ε4 allele (APOEε4) is a major genetic risk factor for Alzheimer's disease (AD). APOEε4 carriers have a higher risk of cognitive impairment and AD in a gene dose-dependent manner. The above notion is investigated in the Greek population.
A sample of 1,703 subjects (967 AD patients, 576 mild cognitive impairment [MCI] and 160 Healthy Elderly), was genotyped for APOE from 2008 to 2017. DNA was extracted from peripheral blood using the QIAamp Blood DNA purification kit (Qiagen Inc., USA). Descriptive statistics, one-way analysis of variance with Bonferroni post hoc tests, Pearson chi-square test, and binary logistic regression models were used for the statistical analysis.
The APOE genotype and allele frequencies in AD group were significantly different from those in the Control and MCI groups. The frequencies of ε4/4 homozygotes were 1.9, 1.6, and 5.7%, while the ε4/- carriers' distribution was 22.5, 24.1, and 37.4% in the Control, MCI, and AD groups respectively. The estimated odds of ε4/4 for AD was 5.731-fold higher compared to the estimated odds of ε3/3. The interaction between gender and APOE did not have a significant effect on the odds for MCI (p = 0.942) and AD (p = 0.984).
In Greece, APOE ε4 presence is related to an increased risk for AD in a dose-related manner. Contrary to long-standing views, men and women with the APOE ε4 genotype have nearly the same odds of developing MCI and AD.
载脂蛋白 E ε4 等位基因(APOEε4)是阿尔茨海默病(AD)的主要遗传风险因素。APOEε4 携带者以基因剂量依赖性方式发生认知障碍和 AD 的风险更高。上述观点在希腊人群中进行了研究。
从 2008 年到 2017 年,对 1703 名受试者(967 名 AD 患者、576 名轻度认知障碍[MCI]和 160 名健康老年人)进行 APOE 基因分型。使用 QIAamp Blood DNA 纯化试剂盒(Qiagen Inc.,美国)从外周血中提取 DNA。采用描述性统计、方差分析(Bonferroni 事后检验)、Pearson 卡方检验和二项逻辑回归模型进行统计学分析。
AD 组的 APOE 基因型和等位基因频率与对照组和 MCI 组有显著差异。ε4/4 纯合子的频率分别为 1.9%、1.6%和 5.7%,而 ε4/-携带者在对照组、MCI 和 AD 组的分布分别为 22.5%、24.1%和 37.4%。与 ε3/3 相比,ε4/4 发生 AD 的估计比值比为 5.731 倍。性别与 APOE 之间的相互作用对 MCI(p=0.942)和 AD(p=0.984)的发生几率没有显著影响。
在希腊,APOEε4 的存在与 AD 风险呈剂量依赖性增加相关。与长期以来的观点相反,携带 APOEε4 基因型的男性和女性发生 MCI 和 AD 的几率几乎相同。